Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 10:56 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 33,128 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PLACEBO Clear all
Terminated Phase 2 Interventional Results available

A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease

NCT01255163
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Exendin-4 SC, Placebo SC
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
60 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Nov 2, 2026, 10:56 PM EST
Completed Not applicable Interventional Results available

USS Virginia Closed-Loop Versus SAP Therapy for Hypoglycemia Reduction in T1D

NCT02302963
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
AP System (DiAs or inControl) with USS Virginia, Sensor-Augmented Pump Therapy (placebo)
Device
Lead sponsor
University of Virginia
Other
Eligibility
12 Years to 70 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Stanford, California • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Nov 2, 2026, 10:56 PM EST
Terminated Phase 1Phase 2 Interventional Results available

Hypertrophic Scar Prevention by Novel Topical Gel Application

NCT03403621
View directory record Official record
Conditions
Hypertrophic Scar
Interventions
Pentamidine Isethionate, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Nov 2, 2026, 10:56 PM EST
Completed Early Phase 1 Interventional

Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer Survivors

NCT03407716
View directory record Official record
Conditions
Cancer Survivor, Stage I Breast Cancer AJCC v7, Stage I Colon Cancer AJCC v6 and v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage II Colon Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIA Colon Cancer AJCC v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIB Colon Cancer AJCC v7, Stage IIC Colon Cancer AJCC v7, Stage III Breast Cancer AJCC v7, Stage III Colon Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Colon Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Colon Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IIIC Colon Cancer AJCC v7
Interventions
American Ginseng, Laboratory Biomarker Analysis, Placebo, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Nov 2, 2026, 10:56 PM EST
Completed Phase 1 Interventional Results available

Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder

NCT01423916
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
OPC-34712 (4mg), Moxifloxacin, OPC-34712 (12mg), Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
8
States / cities
Long Beach, California • San Diego, California • Fort Lauderdale, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Nov 2, 2026, 10:56 PM EST
Completed Phase 2Phase 3 Interventional Results available

Vitamin D/Calcium Polyp Prevention Study

NCT00153816
View directory record Official record
Conditions
Colorectal Cancer, Polyps, Adenomas
Interventions
Calcium Carbonate, Vitamin D3, placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
45 Years to 75 Years
Enrollment
2,813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
10
States / cities
Los Angeles, California • Denver, Colorado • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Nov 2, 2026, 10:56 PM EST
Not listed No phase listed Observational

A Non-Interventional Follow-Up to the VELOUR Study - Translational Research

NCT01754272
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Not listed
Lead sponsor
KU Leuven
Other
Eligibility
18 Years and older
Enrollment
1,226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 21, 2012 · Synced Nov 2, 2026, 10:56 PM EST
Terminated Phase 3 Interventional

GALLANT 9 Tesaglitazar vs. Placebo in Combination With Insulin

NCT00242372
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Tesaglitazar 0.5, Insulin at least 30 units/day
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tuscson, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2009 · Synced Nov 2, 2026, 10:56 PM EST
Completed Phase 2 Interventional Results available

Staccato Loxapine in Agitation (Proof of Concept)

NCT00369577
View directory record Official record
Conditions
Schizophrenia
Interventions
Inhaled Placebo, Inhaled Loxapine 5 mg, Inhaled Loxapine 10 mg
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Upland, California
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Nov 2, 2026, 10:56 PM EST
Completed Phase 3 Interventional Results available

A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma

NCT02161757
View directory record Official record
Conditions
Uncontrolled Asthma
Interventions
Tralokinumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 75 Years
Enrollment
1,207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
103
States / cities
Birmingham, Alabama • Phoenix, Arizona • Arcadia, California + 79 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Nov 2, 2026, 10:56 PM EST
Completed Phase 3 Interventional

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

NCT01993212
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal 12.5 mg or 25 mg, AndroGel 1.62%, Placebo Capsules, Placebo Gel
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
8
States / cities
Jacksonville, Florida • Albany, New York • Raleigh, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Nov 2, 2026, 10:56 PM EST
Active, not recruiting Phase 3 Interventional

A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma

NCT06664619
View directory record Official record
Conditions
Asthma
Interventions
Fp/ABS, FP, ABS, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
12 Years and older
Enrollment
649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
91
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 73 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 2, 2026, 10:56 PM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma

NCT01257230
View directory record Official record
Conditions
Asthma
Interventions
tiotropium Respimat low dose, placebo Respimat, tiotropium Respimat high dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 17 Years
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Plymouth, Minnesota • Columbia, Missouri • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2014 · Synced Nov 2, 2026, 10:56 PM EST
Terminated Not applicable Interventional

The Effects of Inhaled Aromatherapy on Chemotherapy Induced Nausea (CINV) and Vomiting

NCT04478630
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
21 Years to 89 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Nov 2, 2026, 10:56 PM EST
Terminated Phase 2 Interventional Results available

A Study of Aspirin and Simvastatin in Pulmonary Arterial Hypertension

NCT00384865
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Simvastatin, Aspirin, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Nov 2, 2026, 10:56 PM EST
Completed Phase 4 Interventional

Study of the Safety and Efficacy of Moxidectin Tablets for the Reduction of Demodex Eyelash Infestation

NCT06795165
View directory record Official record
Conditions
Blepharitis
Interventions
Moxidectin 2 MG Oral Tablet, Placebo
Drug
Lead sponsor
Eye Research Foundation, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Nov 2, 2026, 10:56 PM EST
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

NCT00297167
View directory record Official record
Conditions
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
EUR-1008 (APT-1008), Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
7 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Nov 2, 2026, 10:56 PM EST
Completed Phase 3 Interventional Results available

A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

NCT00658567
View directory record Official record
Conditions
Parkinson's Disease Psychosis
Interventions
Pimavanserin tartrate (ACP-103)
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
40 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
26
States / cities
La Habra, California • Laguna Hills, California • Reseda, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Nov 2, 2026, 10:56 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

A Pilot Study to Characterize the Bioavailability and Plasma Profile of Potato Polyphenols in Humans

NCT02167607
View directory record Official record
Conditions
Premenopausal Women, Overweight and Obese Women
Interventions
Active Comparator, Placebo Comparator
Dietary Supplement
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Eligibility
20 Years to 45 Years · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Nov 2, 2026, 10:56 PM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder

NCT02066792
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
D-Cycloserine, Placebo, Cognitive Behavioral Therapy
Drug · Behavioral
Lead sponsor
Jasper A. Smits
Other
Eligibility
18 Years to 70 Years
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
3
States / cities
Chicago, Illinois • Boston, Massachusetts • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Nov 2, 2026, 10:56 PM EST
Completed Not applicable Interventional

Evaluation of Vitamin K Supplementation for Calcific Uremic Arteriolopathy

NCT02278692
View directory record Official record
Conditions
Calciphylaxis, Calcific Uremic Arteriolopathy
Interventions
Vitamin K, Placebo
Dietary Supplement · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Nov 2, 2026, 10:56 PM EST
Completed Phase 3 Interventional

Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic Patients(ARPEGGIO)

NCT00288236
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Rimonabant (SR141716), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 7, 2009 · Synced Nov 2, 2026, 10:56 PM EST
Recruiting Phase 4 Interventional Accepts healthy volunteers

The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics

NCT05051436
View directory record Official record
Conditions
Pre-diabetes, Obesity
Interventions
Mirabegron 50 MG, Tadalafil 10 MG, Placebo
Drug
Lead sponsor
Philip Kern
Other
Eligibility
35 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Nov 2, 2026, 10:56 PM EST
Completed Phase 2 Interventional Results available

Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003

NCT00958334
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Proellex®
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
11
States / cities
Phoenix, Arizona • San Diego, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Nov 2, 2026, 10:56 PM EST